Introduction
Blood coagulation is processed by coagulation factors in order to stop the flow of blood through the injured vessel wall whenever an abnormal vascular condition and exposure to non-endothelial surfaces at sites of vascular injury occur (Guyton, 1982; Grey and Meyer, 1988) . As endogenous or exogenous anticoagulants interfered with the coagulation factors, the blood coagulation can be prolonged or stopped (MacFarlane, 1964; Davie and Ratnoff, 1964; Esmon, 2000) . These anticoagulants have been used as convenient tools for the exploration of the complex mechanisms of coagulation cascade. Coincidentally, the importance of research for anticoagulants also arose with therapeutic purposes, for example, a cure for hemophilia. While it was studied for various exogenous anticoagulants (Woo et al., 1996; WaidhetKauadio et al., 1998; Kim et al., 1999) , anticoagulants from marine organisms have rarely been isolated, except for several anticoagulant proteoglycans and polysaccharides from marine algae (Chargaff et al., 1936 Kindness et al., 1980 Maimone and Tollefsen, 1990; McLellan & Jurd, 1991; Jurd et al., 1995) and ascidian tunic (Lee et al., 1998) .
During screening of the anticoagulant activity in marine animals, we recently detected anticoagulant activity from soluble extracts of the blood ark shell, Scapharca broughtonii. In the present paper, we report the purification and properties of the first anticoagulant protein from marine bivalves.
Materials and Methods
Materials Fresh blood ark shells, Scapharca broughtonii, were obtained from a blood ark shell aquafarm (Tongyoung, Korea), and kept under −20 o C until use. HEMOLAB Thrombomatt, HEMOLAB Silimat, and HEMOLAB Cofac reagent for inhibitory assay were obtained from the BioMerieux Co. (Marcy-I'Etoile, France). BioMerieux Coagulometer Option 8 was a product of Behnk Electronic Co. (Norderstedt, Germany). Fibrinogen (from bovine) and urokinase (from human urine) were purchased from the Sigma Chemical Co. (St. Louis, USA). Molecular weight markers for gel filtration and SDS-polyacryl amide gel electrophoresis were products of the Sigma Chemical Co. (Hercules, USA). DEAESephadex A-50, Sephadex G-75, DEAE-Sephacel, and Biogel P-100 were purchased from the Sigma Chemical Co. (St. Louis, USA). ACE homogenizer AM-6 was a product of Nihonseiki Kaisa Ltd. (Tokyo, Japan). The ultramembrane filter, SM165 (Molecular weight, 10 kDa cut-off), for the concentration of protein solutions was obtained from the Sartorious Co. (Göttingen, Germany). All of the other chemicals that were used in this study were of analytical grade and the highest purity. µO XQLWVPOZDVXVHGDVDSRVLWLYHFRQWURO
Purification of the anticoagulant from

Measurement of molecular weight
Amino acid composition The anticoagulant was hydrolyzed with 6 N HCl at 110
4
& for 24 h in vacuum-sealed ampoules. The amino acids were analyzed with an amino acid analyzer (Biochrom 20, Biochrom Ltd., Cambridge, UK). Cysteine residues were estimated by the method of Spencer and Wold (1969) .
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The pH effect of the anticoagulant protein was measured after the protein was incubated in various buffers for 48 h at 4 4 & and neutralized. The following buffers were used: 10 mM glycine-HCl, pH 2.5-3.5; 10 mM acetate, pH 4.0-5.5; 10 mM phosphate, pH 6.0-7.5; 10 mM Tris-HCl, pH 8.0-9.0; 10 mM glycine-NaOH, pH 9.5-11.0. The residual activity was measured by an APTT assay.
The effect on temperature of the anticoagulant was examined after the protein was incubated in a Tris-HCl/EDTA buffer for 15 min at various temperatures. After cooling to room temperature, the residual anticoagulant activity was examined by an APTT assay.
To test the dependency of the anticoagulant activity on cations, the sample solution was dialyzed against 25 mM EDTA in a TrisHCl/EDTA buffer at 4 4 & overnight. Then the solution was dialyzed against deionized water for 24 h in order to remove EDTA. The effect of the cations on APTT was assayed in the presence of various metal cations.
Other methods The protein concentration was determined according to the method of Lowry et al. (1951) using bovine serum albumin as a standard. The protein content in all of the fractions that were obtained during the chromatographic process was estimated by the absorbance at 280 nm.
The sugar content of the purified anticoagulant was determined by the phenol sulfuric acid method of Dubois et al. (1956) 
Results and Discussion
Purification of anticoagulant from S. broughtonii As summarized in Table 1 , purification of the anticoagulant protein from S. broughtonii was accomplished by the following five steps: desalting out with ammonium sulfate, anion exchange chromatography on a DEAE-Sephadex A-50, gel filtration on a Sephadex G-75, and rechromatography on DEAE-Sephacel and Biogel P-100.
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Properties of anticoagulant protein from S. broughtonii
The result of SDS-PAGE was also shown as a homogeneous protein (Fig. 2, insert) . The results of the migration of the incubated anticoagulant protein with 2-mercaptoethanol for 10 min at 95 o C revealed only one band with a molecular mass that corresponded to about 26.0 kDa on gel (Lane 1). In addition, the molecular weight of the intact anticoagulant was also estimated to be 26.0 kDa by gel filtration (Fig. 2) . The presence of a carbohydrate in the purified anticoagulant was not detected by the phenol-sulfuric acid method. In conclusion, the purified anticoagulant from S. broughtonii is considered to be a pure monomeric protein, while most of natural anticoagulant proteins had a high molecular weight. This is shown as a heterogeneous band pattern in SDS-PAGE, and had been found in most glycoproteins (Garfin, 1990) . In addition, inhibitory assays against factor Xa and thrombin (factor IIa) in common pathways suggest that the anticoagulant could not suppress the activation of factor X and the ability of thrombin to convert fibrinogen to fibrin in the common pathways. Apitz-Castro et al. (1995) reported that draculin, an anticoagulant glycoprotein of the activated factor IX, was isolated from the saliva of a vampire bat, Desmodus rotundus. The factor IX-binding protein, a potent anticoagulant against factor IX, was also isolated from the venom of Trimeresurus flavoviridis (Atoda & Morita, 1989) and Deinagkistrodon acutus (Atoda et al., 1998) . But, the anticoagulant against factor IX from marine organisms has not been reported to our knowledge. The fibrinolytic activity of S. broughtonii extract was undetected in the fibrin plate assay, while urokinase lysed the circular area (0.9 mm radius) of the fibrin plate. Some anticoagulant protein, such as the isolated anticoagulant from Lumbricus rubellus (Jeon et al., 1995) , did cleave to both the coagulation factor and fibrin. After 100 µl of 20 mM CaCl 2 was added, the prolongation time (sec) was measured using a Coagulometer Option 8, and exhibited as an inhibitory activity.
Fig. 4.
Inhibition of blood coagulant factors by the purified anticoagulant from S. broughtonii. Inhibition activities for coagulant factors were measured according to the manufacturers instructions. In the inhibition assay for factor IX, 100 µl of HEMOLAB Cofac IX that contained factor IX-deficient human plasma and 100 µl of HEMOLAB Silimat that contained rabbit brain cephaline were incubated with a mixture of citrated normal human plasma (80 µl) and S. broughtonii samples (20 µl). After 100 µl of 20 mM, CaCl 2 was added and the clotting time was measured. The inhibition activity was calculated as a percent (%) unit by a Coagulometer Option 8.
EDTA. But, the activity in the presence of Ca 2+ was more excellent than that of Cu
2+
. This result suggests that copper could play a role as a substitute of the cofactor, Ca 2+ , on the blood coagulation system. As reported by Broze et al. (1990) and Davie et al. (1991) , the factor IXa activated the factor X in the present of Ca 2+ in the intrinsic pathway of the coagulation cascade.
In this study, we discovered that the inhibition mechanism of the anticoagulant from S. broughtonii interrupted the factor IXa activity in the intrinsic pathway of the human coagulation cascade in a Ca 2+ -dependent manner. Its partial properties were also demonstrated. For a complete structure determination and the molecular mechanisms of the factor IX inhibition, further study will progress in our laboratory. 5 . Effects of pH on anticoagulant activity. Residual activity on the APTT assay was measured after the anticoagulant (20 µl, 25 µg/ml) was incubated in the various buffers for 48 h at 4 and neutralized. The following buffers were used: 10 mM glycineHCl, pH 2.5-3.5; 10 mM acetate, pH 4.0-5.5; 10 mM phosphate, pH 6.0-7.5; 10 mM Tris-HCl, pH 8.0-9.0; 10 mM glycine-NaOH, pH 9.5-11.0. 
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